Technology
Health
Biotechnology

Stemline

$13.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.26 (-1.93%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell Stemline and other stocks, options, ETFs, and crypto commission-free!

About STML

Stemline Therapeutics, Inc. Common Stock, also called Stemline, is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Read More Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Employees
92
Headquarters
New York, New York
Founded
2003
Market Cap
586.97M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
369.32K
High Today
$13.59
Low Today
$13.07
Open Price
$13.50
Volume
342.79K
52 Week High
$17.85
52 Week Low
$7.82

Collections

Technology
Health
Biotechnology
Medical
Therapy
Biopharmaceutical
Pharmaceutical
2013 IPO

STML Earnings

-$0.93
-$0.83
-$0.73
-$0.63
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.